{
    "id": 30200,
    "fullName": "FGFR2 - DDX21",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2-DDX21 results from the fusion of FGFR2 and DDX21 (PMID: 30745300). FGFR2-DDX21 has been identified in cholangiocarcinoma (PMID: 30745300, PMID: 28642281), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Feb 2020).",
            "references": [
                {
                    "id": 11306,
                    "pubMedId": 28642281,
                    "title": "Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28642281"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 15194,
                    "pubMedId": 30745300,
                    "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30745300"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "FGFR2 - DDX21",
    "createDate": "05/28/2019",
    "updateDate": "02/03/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 9188,
                "geneSymbol": "DDX21",
                "terms": [
                    "DDX21",
                    "GUA",
                    "GURDB",
                    "RH-II/GU",
                    "RH-II/GuA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 17166,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Debio 1347 treatment resulted in stable disease in a patient with cholangiocarcinoma harboring FGFR2-DDX21 (PMID: 30745300; NCT01948297).",
            "molecularProfile": {
                "id": 32331,
                "profileName": "FGFR2 - DDX21"
            },
            "therapy": {
                "id": 1014,
                "therapyName": "Debio 1347",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15194,
                    "pubMedId": 30745300,
                    "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30745300"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32331,
            "profileName": "FGFR2 - DDX21",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}